<DOC>
	<DOCNO>NCT00169195</DOCNO>
	<brief_summary>The Purpose study evaluate efficacy safety R-GEMOX refractory/relapsed patient CD20-positive large B-cell lymphoma eligible autologous transplantation .</brief_summary>
	<brief_title>Rituximab , Gemcitabine Oxaliplatin ( R-GEMOX ) Refractory/Relapsed B-cell Lymphoma</brief_title>
	<detailed_description>This multicentric , open-label , non-randomized clinical study , evaluate efficacy safety R-GEMOX refractory/relapsed patient age 18 75 year CD20-positive large B-cell lymphoma non eligible autologous transplantation . It anticipate 50 subject enrol 4 year ( April 2003/January 2007 ) , inclusion could stop earlier accord analysis perform every 5 patient ( base triangular test ) . The duration treatment period approximately 16 week patient follow death . The total duration study expect 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients diagnose histologically cytologically proven , CD 20+ , diffuse large Bcell lymphoma , Relapse first second CR , PR le PR firstline treatment rituximabna√Øve patient , OR relapse first second CR minimum delay 12 month last rituximab infusion inclusion rituximabexperienced patient Aged 18 75 year Not eligible autologous transplantation Previously treat chemotherapy contain anthracycline , without rituximab ECOG performance status 0 2 With minimum life expectancy 3 month Having sign informed consent form prior enrollment Burkitt 's , mantle cell , Tcell lymphomas CD 20negative lymphoma HIV HBV related disease Central nervous system meningeal involvement lymphoma Not previously treat anthracyclinecontaining regimen Contraindication drug contain RGEMOX chemotherapy regimen Any serious active disease comorbid medical condition ( accord investigator 's decision ) , Poor renal function ( creatinine level &gt; 150micromol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration Any history cancer last 5 year , exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma Treatment investigational drug within 30 day plan first cycle chemotherapy study Any radiotherapy four week inclusion Pregnant lactate woman Adult patient unable give inform consent intellectual impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>rituximab</keyword>
	<keyword>oxaliplatine</keyword>
	<keyword>gemcitabine</keyword>
</DOC>